Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Jan 13;17(1):97.
doi: 10.3390/ijms17010097.

Nonalcoholic Fatty Liver Disease: Pros and Cons of Histologic Systems of Evaluation

Affiliations
Review

Nonalcoholic Fatty Liver Disease: Pros and Cons of Histologic Systems of Evaluation

Elizabeth M Brunt. Int J Mol Sci. .

Abstract

The diagnostic phenotype of nonalcoholic fatty liver disease (NAFLD)--in particular, the most significant form in terms of prognosis, nonalcoholic steatohepatitis (NASH)--continues to rely on liver tissue evaluation, in spite of remarkable advances in non-invasive algorithms developed from serum-based tests and imaging-based or sonographically-based tests for fibrosis or liver stiffness. The most common tissue evaluation remains percutaneous liver biopsy; considerations given to the needle size and the location of the biopsy have the potential to yield the most representative tissue for evaluation. The pathologist's efforts are directed to not only global diagnosis, but also assessment of severity of injury. Just as in other forms of chronic liver disease, these assessments can be divided into necroinflammatory activity, and fibrosis with parenchymal remodeling, in order to separately analyze potentially reversible (grade) and non-reversible (stage) lesions. These concepts formed the bases for current methods of evaluating the lesions that collectively comprise the phenotypic spectra of NAFLD. Four extant methods have specific applications; there are pros and cons to each, and this forms the basis of the review.

Keywords: nonalcoholic fatty liver disease; nonalcoholic steatohepatitis; pathology.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Ludwig J., Viggiano T.R., McGill D.B., Oh B.J. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin. Proc. 1980;55:434–438. - PubMed
    1. Brunt E.M., Neuschwander-Tetri B.A., Burt A.D. Fatty Liver Disease: Alcoholic and Nonalcoholic. In: Burt A.D., Portmann B., Ferrell L., editors. MacSween’s Pathology of the Liver. 6th ed. Churchill Livingstone/Elsevier; Edinburgh, UK: 2012. pp. 293–359.
    1. Brunt E.M., Wong V.W.-S., Nobili V., Day C.P., Sookoian S., Maher J.J., Sirlin C., Neuschwander-Tetri B.A., Rinella M.E. Nonalcoholic fatty liver disease. Nat. Rev. Prim. 2015 doi: 10.1038/nrdp.2015.80. in press. - DOI - PubMed
    1. Torres D.M., Williams C.D., Harrison S.A. Features, diagnosis, and treatment of nonalcoholic fatty liver disease. Clin. Gastroenterol. Hepatol. 2012;10:837–858. doi: 10.1016/j.cgh.2012.03.011. - DOI - PubMed
    1. Ratziu V., Charlotte F., Heurtier A., Gombert S., Giral P., Bruckert E., Grimaldi A., Capron F., Poynard T. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology. 2005;128:1898–1906. doi: 10.1053/j.gastro.2005.03.084. - DOI - PubMed

LinkOut - more resources